Teza Capital Management LLC boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 732.4% during the first quarter, Holdings Channel reports. The fund owned 17,230 shares of the medical research company’s stock after buying an additional 15,160 shares during the period. Thermo Fisher Scientific accounts for about 0.8% of Teza Capital Management LLC’s holdings, making the stock its 13th largest position. Teza Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $2,647,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Intrust Bank NA increased its stake in Thermo Fisher Scientific by 5.5% in the first quarter. Intrust Bank NA now owns 2,562 shares of the medical research company’s stock worth $394,000 after buying an additional 134 shares during the last quarter. Gabelli Funds LLC increased its stake in Thermo Fisher Scientific by 5.1% in the first quarter. Gabelli Funds LLC now owns 145,500 shares of the medical research company’s stock worth $22,349,000 after buying an additional 7,000 shares during the last quarter. Connable Office Inc. increased its stake in Thermo Fisher Scientific by 12.2% in the first quarter. Connable Office Inc. now owns 21,969 shares of the medical research company’s stock worth $3,374,000 after buying an additional 2,397 shares during the last quarter. World Asset Management Inc increased its stake in Thermo Fisher Scientific by 13.3% in the first quarter. World Asset Management Inc now owns 40,150 shares of the medical research company’s stock worth $6,167,000 after buying an additional 4,705 shares during the last quarter. Finally, Icon Advisers Inc. Co. increased its stake in Thermo Fisher Scientific by 13.7% in the first quarter. Icon Advisers Inc. Co. now owns 51,400 shares of the medical research company’s stock worth $7,895,000 after buying an additional 6,200 shares during the last quarter. Institutional investors own 86.89% of the company’s stock.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc (NYSE:TMO) opened at 174.86 on Friday. The stock has a market capitalization of $68.41 billion, a P/E ratio of 31.90 and a beta of 1.05. The company’s 50-day moving average price is $172.39 and its 200 day moving average price is $156.39. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $176.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 26th. The medical research company reported $2.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.02 by $0.06. The business had revenue of $4.77 billion during the quarter, compared to analysts’ expectations of $4.68 billion. Thermo Fisher Scientific had a return on equity of 15.73% and a net margin of 11.58%. Thermo Fisher Scientific’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.80 earnings per share. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc will post $9.22 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 17th. Stockholders of record on Thursday, June 15th will be given a $0.15 dividend. The ex-dividend date is Tuesday, June 13th. This represents a $0.60 annualized dividend and a dividend yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.95%.

TRADEMARK VIOLATION NOTICE: “Teza Capital Management LLC Has $2.65 Million Stake in Thermo Fisher Scientific Inc (TMO)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/teza-capital-management-llc-has-2-65-million-stake-in-thermo-fisher-scientific-inc-tmo/1371823.html.

A number of analysts have commented on the company. Deutsche Bank AG set a $200.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Saturday, June 10th. Cantor Fitzgerald assumed coverage on Thermo Fisher Scientific in a research report on Thursday, May 18th. They set an “overweight” rating and a $194.00 target price on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $175.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, May 17th. Barclays PLC reiterated an “overweight” rating and set a $190.00 target price (up from $175.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, May 9th. Finally, Bank of America Corporation boosted their target price on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $183.47.

In other news, insider Thomas W. Loewald sold 1,532 shares of the firm’s stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $168.76, for a total value of $258,540.32. Following the completion of the sale, the insider now owns 41,277 shares of the company’s stock, valued at $6,965,906.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Daniel P. Shine sold 4,688 shares of the firm’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total value of $805,773.44. Following the completion of the sale, the insider now directly owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,720 shares of company stock valued at $4,960,764. 0.49% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.